|
Cyclacel Pharmaceuticals, Inc. (CYCC) Avaliação DCF
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Totalmente Editável: Adapte-Se Às Suas Necessidades No Excel Ou Planilhas
- ✓ Design Profissional: Modelos Confiáveis E Padrão Da Indústria
- ✓ Pré-Construídos Para Uso Rápido E Eficiente
- ✓ Não É Necessária Experiência; Fácil De Seguir
Cyclacel Pharmaceuticals, Inc. (CYCC) Bundle
Simplifique a avaliação Cyclacel Pharmaceuticals, Inc. (CYCC) com esta calculadora DCF personalizável! Apresentando o Cyclacel Pharmaceuticals, Inc. (CYCC) real e os insumos de previsão ajustável, você pode testar vários cenários e descobrir o valor justo da Cyclacel Pharmaceuticals, Inc. (CYCC) em apenas alguns minutos.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | .0 | .0 | .0 | .4 | .4 | .4 | .4 | .4 | .4 |
| Revenue Growth, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITDA | -9.7 | -10.6 | -22.7 | -27.6 | -25.4 | .3 | .3 | .3 | .3 | .3 |
| EBITDA, % | 100 | 100 | 100 | 100 | -6052.86 | 60 | 60 | 60 | 60 | 60 |
| Depreciation | .0 | .0 | .0 | .0 | .0 | .3 | .3 | .3 | .3 | .3 |
| Depreciation, % | 100 | 100 | 100 | 100 | 7.38 | 81.48 | 81.48 | 81.48 | 81.48 | 81.48 |
| EBIT | -9.7 | -10.6 | -22.7 | -27.7 | -25.5 | .3 | .3 | .3 | .3 | .3 |
| EBIT, % | 100 | 100 | 100 | 100 | -6060.24 | 60 | 60 | 60 | 60 | 60 |
| Total Cash | 11.9 | 33.4 | 36.6 | 18.3 | 3.4 | .4 | .4 | .4 | .4 | .4 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 1.3 | 1.3 | .0 | .0 | 2.9 | .4 | .4 | .4 | .4 | .4 |
| Account Receivables, % | 100 | 100 | 100 | 100 | 698.33 | 100 | 100 | 100 | 100 | 100 |
| Inventories | .7 | .7 | .6 | -5.6 | .0 | .3 | .3 | .3 | .3 | .3 |
| Inventories, % | 100 | 100 | 100 | 100 | 0 | 80 | 80 | 80 | 80 | 80 |
| Accounts Payable | .9 | .5 | 2.1 | 2.6 | 3.5 | .4 | .4 | .4 | .4 | .4 |
| Accounts Payable, % | 100 | 100 | 100 | 100 | 843.57 | 100 | 100 | 100 | 100 | 100 |
| Capital Expenditure | .0 | -.1 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | 100 | 100 | 100 | 100 | -1.43 | -0.28571 | -0.28571 | -0.28571 | -0.28571 | -0.28571 |
| Tax Rate, % | 11.73 | 11.73 | 11.73 | 11.73 | 11.73 | 11.73 | 11.73 | 11.73 | 11.73 | 11.73 |
| EBITAT | -8.3 | -9.3 | -18.9 | -22.6 | -22.5 | .2 | .2 | .2 | .2 | .2 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -9.4 | -9.7 | -15.8 | -15.9 | -30.0 | -.4 | .6 | .6 | .6 | .6 |
| WACC, % | 5.43 | 5.43 | 5.42 | 5.41 | 5.44 | 5.43 | 5.43 | 5.43 | 5.43 | 5.43 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 1.5 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 1 | |||||||||
| Terminal Value | 17 | |||||||||
| Present Terminal Value | 13 | |||||||||
| Enterprise Value | 14 | |||||||||
| Net Debt | -3 | |||||||||
| Equity Value | 18 | |||||||||
| Diluted Shares Outstanding, MM | 1 | |||||||||
| Equity Value Per Share | 20.60 |
What You Will Get
- Editable Forecast Inputs: Easily modify assumptions (growth %, margins, WACC) to explore various scenarios.
- Real-World Data: Cyclacel Pharmaceuticals’ financial data pre-filled to kickstart your analysis.
- Automatic DCF Outputs: The template computes Net Present Value (NPV) and intrinsic value for you.
- Customizable and Professional: A refined Excel model that adjusts to your valuation requirements.
- Built for Analysts and Investors: Perfect for evaluating projections, confirming strategies, and saving time.
Key Features
- Comprehensive DCF Analysis Tool: Offers detailed unlevered and levered DCF valuation models tailored for Cyclacel Pharmaceuticals, Inc. (CYCC).
- WACC Calculation Module: Features a pre-built Weighted Average Cost of Capital sheet with adjustable parameters.
- Customizable Forecast Inputs: Adapt growth projections, capital expenditures, and discount rates as needed.
- Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency ratios specific to Cyclacel Pharmaceuticals, Inc. (CYCC).
- Interactive Dashboard and Visualizations: Graphical representations summarize essential valuation metrics for straightforward analysis.
How It Works
- Download: Obtain the pre-configured Excel file featuring Cyclacel Pharmaceuticals, Inc.'s (CYCC) financial data.
- Customize: Modify projections, such as revenue growth, EBITDA %, and WACC.
- Update Automatically: The intrinsic value and NPV calculations refresh in real-time.
- Test Scenarios: Develop various projections and instantly compare results.
- Make Decisions: Utilize the valuation findings to inform your investment strategy.
Why Choose This Calculator for Cyclacel Pharmaceuticals, Inc. (CYCC)?
- All-in-One Solution: Combines DCF, WACC, and financial ratio analyses tailored for Cyclacel Pharmaceuticals.
- Flexible Inputs: Modify the yellow-highlighted cells to explore different financial scenarios for (CYCC).
- In-Depth Analysis: Automatically computes Cyclacel's intrinsic value and Net Present Value.
- Preloaded Information: Historical and projected data provide reliable starting points for analysis.
- Expert-Level Tool: Perfect for financial analysts, investors, and consultants focusing on (CYCC).
Who Should Use This Product?
- Investors: Accurately assess Cyclacel Pharmaceuticals’ (CYCC) fair value prior to making investment choices.
- CFOs: Utilize a professional-grade DCF model for financial reporting and analysis specific to Cyclacel Pharmaceuticals.
- Consultants: Efficiently customize the template for valuation reports tailored to Cyclacel Pharmaceuticals’ clients.
- Entrepreneurs: Acquire knowledge on financial modeling techniques employed by top-tier pharmaceutical companies.
- Educators: Implement it as a teaching resource to illustrate valuation methodologies in the pharmaceutical sector.
What the Template Contains
- Comprehensive DCF Model: Editable template featuring in-depth valuation calculations.
- Real-World Data: Cyclacel Pharmaceuticals' (CYCC) historical and projected financials preloaded for analysis.
- Customizable Parameters: Modify WACC, growth rates, and tax assumptions to explore various scenarios.
- Financial Statements: Complete annual and quarterly breakdowns for enhanced insights.
- Key Ratios: Integrated analysis for profitability, efficiency, and leverage metrics.
- Dashboard with Visual Outputs: Charts and tables designed for clear, actionable results.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.